Day: February 7, 2025

SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 164,000 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $8.25 per share, the Company’s closing sales price on February 3, 2025,...

– University of Waterloo’s Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award – – Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay the groundwork for an exciting new brain model initiative to be revealed soon – KENMORE, N.Y., Feb. 07, 2025 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to congratulate Christopher Wilson, PhD, on being recognized by the University of Waterloo’s (“UW”) Faculty of Engineering for his significant contributions to research and scholarship. The award recognizes Dr. Wilson’s research at the Institute...

MONTVALE, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, February 21, 2025, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2024 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year results will be published prior to the market opening on Friday, February 21, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call. The conference call will be available for...

–-ORLYNVAHTM Approved by FDA in Q4 2024— –-Extended Cash Runway– –Company to host conference call today at 8:30amET– DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2024. “While outreach to potential strategic partners is our priority and ongoing, we have begun pre-commercialization work to ensure ORLYNVAHTM is made available to patients as soon as possible to address the substantial unmet need for effective treatment options for uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Iterum’s...

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to 5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia. Please see full Prescribing Information for PEDMARK® at: www.PEDMARK.com. About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe...

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings. Details are as follows:Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceDate: February 11-12, 2025Presentation:   Tuesday, February 11, 2025, 10:00 AM ETWebcast Link: https://wsw.com/webcast/oppenheimer39/opt/2588856The webcast will also be accessible on the “Events & Presentations” section of the Company’s...

SANTA CLARA, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) — Agora, Inc. (NASDAQ: API), a pioneer and leader in real-time engagement technology, will release its financial results for the fourth quarter and fiscal year ended December 31, 2024 after the close of U.S. markets on February 24, 2025. Agora, Inc. will host a conference call to discuss the financial results at 5 p.m. Pacific Time / 8 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 4Q 2024 Financial Results The call will be available at https://edge.media-server.com/mmc/p/ca3ihsn6 Investors who want to hear the call should log on at least 15 minutes prior to the broadcast. Participants may register for the call with the link below. https://register.vevent.com/register/BIaffae7deb01345b39b477ccdbc209daa Please visit Agora,...

MONTREAL, Feb. 07, 2025 (GLOBE NEWSWIRE) —Open to: Analysts, investors and all interested partiesDATE: Friday, February 14, 2025TIME: 8:30 AM Eastern TimeCALL: 412-317-5413 (For all International participants)1-866-777-2509 (For all other North American participants)   Participants can register for the conference by navigating to: https://dpregister.com/sreg/10196704/fe744787a0 Please note that registered participants will receive their dial in number upon registration. Pre-registration fields of information to be gathered:  Name, Phone, Company THE FOURTH QUARTER RESULTS will be PUBLISHED FEBRUARY 14, 2025 BEFORE THE CONFERENCE CALL. Please dial in 15 minutes before the conference begins. If you are unable to call in at this time, you may access a recording of the meeting by calling the following: US Toll Free:...

Cutting-Edge Technology Selected to Secure Patient and Staff Experiences to Prioritize Care TORONTO, Feb. 07, 2025 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its Xtract One Gateway (“Gateway”) has been selected to protect key hospital locations in Manitoba, including at the province’s Health Sciences Centre and Crisis Response Centre locations operated by Shared Health. The system will redefine the security experience by not only balancing powerful threat detection with seamless flow for individuals, but also enhancing safety standards and optimizing operational efficiency. “Healthcare environments today face two security challenges: providing top-tier security while ensuring that both patients and caregivers feel safe and comfortable,”...